Short-term risk of AIDS or death in people infected with HIV-1 before antiretroviral therapy in South Africa: a longitudinal study

Lancet

Volumn 368, Issue 9543, 2006, Pages 1254-1259

  Badri, Motasim ^a   Lawn, Stephen D ^a,b   Wood, Robin ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CALCULATION; CAUSE OF DEATH; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; SOUTH AFRICA; WORLD HEALTH ORGANIZATION;

EID: 33749445792     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(06)69117-4     Document Type: Article

References (34)

1. WHO/UNAIDS. Progress of global access to HIV antiretroviral therapy. An update on '3 by 5' (June 2005). http://www.who.int/hiv/pub/progressreports/3by5%20Progress%20Report_E_li ght.pdf (accessed March 27, 2006)
2. WHO/UNAIDS. Press release: HIV infection rates decreasing in several countries but global number of people living with HIV continues to rise (November, 2005). http://www.who.int/hiv/epiupdate2005/en/print.html (accessed March 27, 2006)
3. Cleary S., Boulle A., McIntyre D., and Coetzee D. Cost-effectiveness of antiretroviral treatment for HIV-positive adults in a South African township (2004). http://www.hst.org.za/uploads/files/arv_cost.pdf (accessed March 27, 2006)
4. Badri M., Maartens G., Mandalia S., et al. Cost-effectiveness of highly active antiretroviral therapy in South Africa. PLoS Med 1 (2006) e4
5. Badri M., Cleary S., Maartens G., et al. When to initiate highly active antiretroviral therapy in sub-Saharan Africa? A South African cost-effectiveness study. Antivir Ther 11 (2006) 63-72
6. Mellors J., Rinaldo C., Gupta P., et al. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 272 (1996) 1167-1170
7. 6/l. AIDS 10 (1996) F39-F44
8. + lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 126 (1997) 946-954
9. de Wolf F., Spijkerman I., Schellekens P., et al. AIDS prognosis based on HIV-1 RNA, CD4 T-cell count and function: markers with reciprocal predictive value over time after seroconversion. AIDS 11 (1997) 1799-1806
10. + count on the rate of progression of HIV-1 infection to AIDS. J Acquir Immune Defic Syndr 15 (1997) 243-244
11. Sabin C., Devereux H., Phillips A., Janossy G., Loveday C., and Lee C. Immune markers and viral load after HIV-1 seroconversion as predictors of disease progression in a cohort of haemophilic men. AIDS 12 (1998) 1347-1352
12. Cozzi Lepri A., Katzenstein T., Ullum H., et al. The relative prognostic value of plasma HIV RNA levels and CD4 lymphocyte counts in advanced HIV infection. AIDS 12 (1998) 1639-1643
13. Panel on Clinical Practices for Treatment of HIV Infection, US Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents (Oct 6, 2005). http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf (accessed March 27, 2006)
14. European AIDS Clinical Society. European guidelines for the clinical management and treatment of HIV infected adults in Europe. http://www.eacs.ws/download/Euroguidelines4151105.pdf (accessed March 27, 2006)
15. The British HIV Association. BHIVA guidelines for the treatment of HIV-infected adults with antiretroviral therapy (July 2005). http://www.bhiva.org/guidelines/2005/HIV/HIV05frameset.html (accessed March 27, 2005)
16. WHO. Scaling up antiretroviral therapy in resource-limited settings: treatment guidelines for a public health approach (2003). http://www.who.int/hiv/pub/prev_care/en/arvrevision2003en.pdf (accessed March 27, 2005)
17. WHO guidelines development group. Antiviral drugs for the treatment of HIV infection in adults and adolescents in resource-limited settings: recommendations for a public health approach: brief meeting report 2005-2006 (June 2005). http://www.who.int/3by5/ARVmeetingreport_June2005.pdf (accessed March 27, 2006)
18. Bogaards J., Weverling G., Zwinderman A., Bossuyt M., and Goudsmit J. Plasma HIV-1 RNA to guide patient selection for antiretroviral therapy in resource-poor settings. J Acquir Immune Defic Syndr 41 (2006) 232-237
19. CASCADE collaboration. Short-term risk of AIDS according to current CD4 cell count and viral load in antiretroviral drug-naïve individuals and those treated in the montherapy era. AIDS 1 (2004) 51-58
20. Badri M., Wilson D., and Wood R. Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet 359 (2002) 2059-2064
21. Badri M., Bekker L., Orrell C., Pitt J., Cilliers F., and Wood R. Initiating highly active antiretroviral therapy in sub-Saharan Africa: an assessment of the revised World Health Organization scaling-up guidelines. AIDS 8 (2004) 1159-1168
22. WHO. Acquired immunodeficiency syndrome (AIDS): interim proposal for a WHO staging system for HIV infection and disease. Wkly Epidemiol Rec 65 (1990) 221-224
23. Morgan D., Mahe C., Mayanja B., Okongo J., Lubega R., and Whitworth J. HIV-1 infection in rural Uganda: is there a difference in median time to AIDS and survival compared with that in industrialised countries?. AIDS 16 (2002) 597-603
24. Colebunders R., Ryder R., Francis H., et al. Seroconversion rate, mortality, and clinical manifestations associated with the receipt of a human immunodeficiency virus-infected blood transfusion in Kinshasa, Zaire. J Infect Dis 3 (1991) 450-456
25. Lindan C., Allen S., Serufilira A., et al. Predictors of mortality among HIV-infected women in Kigali, Rwanda. Ann Intern Med 4 (1992) 320-328
26. Whittle H., Egboga A., Todd J., et al. Clinical and laboratory predictors of survival in Gambian patients with symptomatic HIV-1 or HIV-2 infection. AIDS 7 (1992) 685-689
27. Malamba S., Morgan D., Clayton T., Mayanja B., Okongo M., and Whitworth J. The prognostic value of the World Health Organisation staging system for HIV infection and disease in rural Uganda. AIDS 18 (1999) 2555-2562
28. Scott J., Hall A., Muyodi C., et al. Aetiology, outcome, and risk factors for mortality among adults with acute pneumonia in Kenya. Lancet 355 (2000) 1225-1230
29. Post F., Badri M., Wood R., and Maartens G. AIDS in Africa: survival according to AIDS-defining illness. S Afr Med J 7 (2001) 583-586
30. Alabi A., Jaffar S., Ariyoshi K., et al. Plasma viral load, CD4 cell percentage, HLA and survival of HIV-1, HIV-2, and dually infected Gambian patients. AIDS 10 (2003) 1513-1520
31. Wood R. Should we be initiating antiretroviral therapy earlier? An argument in favour. S Afr Med J 12 (2005) 926-927
32. Lawn S., Myer L., Orrell C., Bekker L., and Wood R. Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design. AIDS 19 (2005) 2141-2148
33. Rabkin M., El-Sadr W., Katzenstein D., et al. Antiretroviral treatment in resource-poor settings: clinical research priorities. Lancet 360 (2002) 1503-1505
34. Schluchter M. Methods for the analysis of informatively censored longitudinal data. Stat Med 11 (1992) 1861-1870